Presentation at this notable obesity-related medical conference reviewed nimacimab’s differentiated characteristics, reiterated meaningful weight loss data from a pre-clinical diet-induced obesity model, and introduced new biomarker data showing important reductions in obesity-induced inflammation and liver steatosis.